# Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2

Study · id `cardio:ct-nct01763827` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01763827](<https://clinicaltrials.gov/study/NCT01763827>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01763827

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 615 participants.

## Technical summary

Registry record NCT01763827. Randomized; quadruple masking; primary purpose treatment. Start 2013-01-21 (actual); primary completion 2013-10-10 (actual). Results posted on 2015-12-30.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 615 participants (enrolled count; ClinicalTrials.gov record NCT01763827, source copy `cardio:ctgov-nct01763827-2022-11-08`, retrieved 2026-10-31)
- Started: 2013-01-21 (actual) (ClinicalTrials.gov record NCT01763827, source copy `cardio:ctgov-nct01763827-2022-11-08`, retrieved 2026-10-31)
- Primary completion: 2013-10-10 (actual) (ClinicalTrials.gov record NCT01763827, source copy `cardio:ctgov-nct01763827-2022-11-08`, retrieved 2026-10-31)
- Completion: 2013-10-29 (actual) (ClinicalTrials.gov record NCT01763827, source copy `cardio:ctgov-nct01763827-2022-11-08`, retrieved 2026-10-31)
- Results first posted: 2015-12-30 (ClinicalTrials.gov record NCT01763827, source copy `cardio:ctgov-nct01763827-2022-11-08`, retrieved 2026-10-31)
- Countries: United States; Australia; Belgium; Canada; Denmark; France; South Africa; South Korea; Taiwan; Türkiye (ClinicalTrials.gov record NCT01763827, source copy `cardio:ctgov-nct01763827-2022-11-08`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01763827-2022-11-08`, retrieved 2026-10-31)

## The registry's words

- Brief title: Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2
- Acronym: MENDEL-2
- Condition: Hyperlipidemia
- Intervention (Biological): Evolocumab
- Intervention (Drug): Ezetimibe
- Intervention (Biological): Placebo to Evolocumab
- Intervention (Other): Placebo to Ezetimibe
- Lead sponsor: Amgen
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry intervention name matches this record: Evolocumab (`cardio:evolocumab`)
- Registry intervention name matches this record: Ezetimibe (`cardio:ezetimibe`)
- Registry lists this organization as the lead sponsor: Amgen (`cardio:org-amgen`)

## Provenance

Content hash: 3d2582303ff3b26e30b4fc31d9e9fb3db7b8b8b7bf89f1657491959d48c03e18
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
